#acute myeloid leukemia | Explore Tumblr Posts and Blogs

moriparty413 · 1 year

Text

happy pope listening to megalovania anniversary eve. as much as i don't want to think about it, it's also the one year anniversary of the urfaveisunfuckable disaster, and some of you may remember me as mod gortys (or mori or rhys. yes my name is rhys. no im not mod rhys. we're two different people with the same name. it happens.) i wouldn't be making this post if i wasn't absolutely desperate, so if you were at all entertained by that clusterfuck, please do me a favor and just read.

i've made this announcement before, but i was diagnosed with acute myeloid leukemia at the end of september (which is leukemia awareness month, ironically enough.) needless to say, chemo is expensive. i was a college student who was only able to go on scholarship, and the scholarship was rapidly becoming not enough. my parents are both teachers, a job that notoriously never pays well, and my dad quit to be able to take time to take me to my appointments.

my aunt made a gofundme for my care, and the reason i'm so hesitant to link it is that she included my legal name and face, and i know that many people on this site are no better off than me. i am truly desperate, as i spent the majority of october and november in this hospital and this is, needlessly to say, a huge obstacle to getting a job. even though i'm now in remission (not completely, there's some residual left), i'm still going to have to get maintenance chemo about once a month, and the only way to completely ensure i don't have a relapse is to get a bone marrow transplant. this would mean i'll have to stay in the hospital for another month, have visits three times a week for another 3 months, and then have visits slowly getting less often for another 3 months. even then, i'll have to have more frequent checkups for the rest of my life just to make sure i stay well.

even if you can only signal boost, not donate, i would greatly appreciate it. if i had a dollar for every note on that video recapping the drama, i'd have at least 43k. any amount of help would be appreciated. we've only reached about 4k, and while i'm grateful and surprised that we even reached that much, it just isn't enough for all the expenses that will be piling on. thank you for your time.

also, if you are able to donate, please don't send any comments with the names mori or rhys on them, i'm not out to my parents in any capacity and this i don't want to come out to them while i'm so dependent on them. thank you for your understanding.

#urfaveisunfuckable #ufiu #ufiu fiasco #gofundme #leukemia #cancer #acute myeloid leukemia #again. i wouldn't be bringing up what happened unless i was truly desperate #i hated how people focused on the nfts instead of being an abuser.#both actions were wrong but you have to admit that abuse is incredibly serious and no laughing matter #im also sorry to my fellow former mods for bringing this up again but like i said. im desperate

2K notes · View notes

bpod-bpod · 1 year

Photo

Blast Zone

An aggressive blood cancer, acute myeloid leukaemia (AML) occurs when abnormal developing white blood cells, known as blasts, start to multiply rapidly, filling up the bone marrow and disrupting the development of other blood cells. Pictured here are blasts (in purple) surrounded by red blood cells, from the bone marrow of a patient with Down syndrome; children with Down’s, a genetic condition caused by carrying a third copy of chromosome 21, are at much greater risk of developing AML. To understand why, researchers used gene editing tools to investigate all 218 genes on this extra chromosome. They homed in on RUNX1, which encodes a transcription factor, a protein that regulates other genes. RUNX1 can be expressed in several forms, and balance between them is key: these recent experiments suggest that AML is linked to an excess of a form called RUNX1A, opening up new avenues for research into potential treatments.

Written by Emmanuelle Briolat

Image by Jan Klusmann, University Hospital Frankfurt

Department of Pediatrics, Goethe University Frankfurt, Frankfurt am Main, Germany

Image copyright held by the original authors

Research published in Blood, March 2023

You can also follow BPoD on Instagram, Twitter and Facebook

#science #biomedicine #haemopoiesis #leukaemia #hemato oncology testing #hematooncology #oncology #haematology #Blood #bone marrow #may grunwald giemsa #runx1 #down syndrome #chromosome 21 #acute myeloid leukemia

17 notes · View notes

let-bucky-be-happy · 1 year

Text

Hello hi yes, I'm alive, just got busy trying not to literally die of cancer (acute myeloid leukemia if we're being specific) but I'm surviving, I was in remission for a bit but relapsed in December. It's been a hell of a ride but hopefully my stem cell transplant will end it before it ends me.

And the salt in the gaping and bleeding wound? My aunt's cat died right before Christmas. He was my best little buddy but I guess every old cat goes eventually, he at least went peacefully in his sleep.

#fuck cancer #acute myeloid leukemia #why did it have to be me #i didn't deserve cancer #2022 was rough

7 notes · View notes

jppres · 1 year

Text

Anti-leukemic activity of Cyperus rotundus L.on human acute myeloid leukemia HL-60 cells in vitro

Image: Flickr Article published in J. Pharm. Pharmacogn. Res., vol. 11, no. 1, pp. 191-197, January-February 2023. DOI: https://doi.org/10.56499/jppres22.1502_11.1.191 Sulistyo Mulyo Agustini1, Edi Widjajanto2, Muhaimin Rifa’i3, Sofia Mubarika Haryana4, Nurdiana5, Diana Lyrawati5, Usi Sukorini6, Noviana Dwi Lestari7* 1Department of Pathology, Faculty of Medicine, Muhammadiyah Malang…

View On WordPress

#acute myeloid leukemia #Apoptosis #cell cycle #Cyperus rotundus #HL-60 cells line

2 notes · View notes

mecolin50 · 6 months

Text

THANKFUL & HOPEFUL

In the Spring March 1st of 2023, my life took an unexpected turn when I was diagnosed with Acute Myeloid Leukemia (AML). The news was crushing, but little did I know that the National Health Service (NHS) would become my beacon of hope, pulling me from the jaws of certain death.

The early days were a whirlwind of tests, consultations, and preparations for treatment. The NHS staff worked tirelessly to ensure that every aspect of my care was meticulously planned. Their expertise and dedication were palpable, offering me not only medical support but also a glimmer of optimism in the face of adversity.

As I embarked on chemotherapy, the NHS stood as a formidable fortress between life and death. The precision and care with which the treatment was administered were awe-inspiring. The nurses, the unsung heroes of healthcare, became my pillars of strength. They navigated the delicate balance between compassion and professionalism with grace, offering comfort during my weakest moments.

After months of grueling treatment, the prospect of a bone marrow transplant emerged as my best chance for survival. The NHS orchestrated a symphony of coordination to find a suitable donor, a feat that could not be underestimated. The logistical challenges were immense, yet the NHS team tackled them head-on, leaving no stone unturned in their quest to save my life.

#cancer #bone marrow transplant #acute myeloid leukemia

0 notes

stomeranclels451 · 1 year

Text

https://demo.sngine.com/blogs/173909/Dental-Amalgam-Market-Players-Overview-and-Growth-Prospects-by-2030

Acute Myeloid Leukemia Treatment Market Share, Growth Factors and Forecast to 2030

#Acute Myeloid Leukemia

0 notes

heighpubs · 1 year

Text

#Absorptiometry #Acute Lymphoblastic Leukemia #Acute Myeloid Leukemia #Adenocarcinoma of the Lung #Adenocarcinomas

0 notes

ijcimr · 1 year

Text

An ‘Uncommon early lineage switch’ in an MLL rearranged adult B-lineage Acute Lymphoblastic Leukemia to Mixed-phenotypic acute leukemia (B/Myeloid) by Narendra Agrawal in International Journal of Clinical Images and Medical Reviews

Case Report

Lineage switch is an infrequent phenomenon with an incidence of ~ 0.6% of all de novo leukemias and seen in almost 6% of relapsed cases. This phenomenon is observed following therapy or at the time of relapse. Switch in lineage tends to occur in younger patients and is associated with particularly poor outcomes.[1]

https://ijcimr.org/wp-content/uploads/2022/01/Fig-1__1_.jpg

Discussion

Our clinical report illustrates an adult refractory B -ALL with t (4;11) (q21;23), AF4:MLL fusion who transformed to Mixed-phenotypic acute leukemia;KMT2A-rearranged during his second month of therapy. Lineage switch in MLL rearranged paediatric ALL is common, but in adults it is not well reported. During the literature review, we found 2 cases of adult ALL harbouring t (4;11) transformed to AML [1,4]. First case illustrated chemotherapy responsive MLL rearranged B-ALL who underwent allogeneic stem cell transplantation (Allo SCT) in remission after induction therapy, who transformed to AML post 100 days of Allo SCT[4]. Second case illustrated refractory MLL rearranged B-ALL adult that rapidly transformed to AML following initiation of blinatumomab therapy [1]. However there was no case found to have switched from B acute lymphoblastic leukemia to Mixed-phenotypic acute leukemia;KMT2A-rearranged .Mechanism for lineage switch in MLL rearranged acute leukemia is not clear yet. Reports showing a strong trend of lineage switch involving B and myeloid lineages suggest that B myeloid progenitor might be involved in the mechanism of lineage switch. Studies reporting lineage switch post anti CD19 therapy; blinatumomab and CD19 chimeric antigen receptor (CAR-T), further advocates this theory [3].In our case it is not possible to state that transformation occurred post Venetoclax therapy, as flow cytometric evaluation was not done prior to start of venetoclax therapy. Development of secondary AML as a result of therapy related process can be ruled out in view of early lineage switch (< 6 months of therapy) and consistent finding of the t (4;11) (q21;23) at diagnosis of B-ALL and transformation. The (4;11) rearrangement detected at diagnosis, and phenotypic switch suggests that the original clone harboured a bi-lineage potential. If further genetic studies including NGS or gene expression studies done at baseline could have predicted the bi lineage potential is also unclear as the case reported by Haddox C et al did not show any change in the baseline NGS and the NGS performed during relapse.In conclusion, haematologists should be cognizant while treating MLL rearranged B -ALL adults for a lineage switch. It also underlies the importance of repeat evaluation of the disease if there is no response to standard therapy.

Declarations

Funding Funding information is not applicable to this study.Conflict of Interest All authors declare no conflict of interest to declare.Compliance with Ethical Standards Ethical Approval Statement: All authors stated that the study has been approved by the appropriate institutional review board and have been performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.Acknowledgement We are thankful to our RGCI & RC staff of department of Hematology for their constant supportFor more details: https://ijcimr.org/editorial-board/

#Lineage switch #phenomenon #ALL #Mixed leukemia lineage #acute lymphoblastic leukemia #AML #MLL #acute myeloid leukemia #CD #chemotherapy #dysfunction syndrome #Ara-C #Narendra Agrawal

1 note · View note

jcrmhscasereports · 1 year

Text

ACUTE MYELOID LEUKEMIA IN PREGNANCY: DIFFICULT JOURNEY FROM DIAGNOSIS TO DELIVERY AND TREATMENT by Vina Kumari in Journal of Clinical Case Reports Medical Images and Health Sciences

ABSTRACT

The incidence of Acute Myeloid Leukemia in pregnancy is about 1 in 75,000 to 1 in 100,000. Owing to the therapy attributable risks to mother and fetus, the management of AML in pregnancy is very challenging, both for the parents and the medical fraternity. Furthermore, the diagnosis of leukemia in pregnancy is very difficult owing to vague presenting symptoms like fatigue and weakness which are confused with physiological changes during pregnancy.

Case Report: Primigravida, 33 weeks 6 days gestation age, with history of weakness and fatigue for 15 days and fever, cough and cold for 3 days was referred to our hospital with blood reports of raised total leucocyte count. The lab reports showed thrombocytopenia, anemia and leukocytosis with increased circulating blasts in the peripheral smear. As she was in her third trimester, plan of induction of labor and delivery followed by chemotherapy was taken. She delivered a live healthy baby. Post-delivery, she was advised chemotherapy. She had an immediate remission after the chemotherapy. The disease relapsed after 10 months and she succumbed to the disease due to unavailability of facilities during the COVID pandemic.

Conclusion: AML during pregnancy is rare. There is no fixed protocol for management of AML during pregnancy .The aim of management should be to take care of the initial concerns regarding fetal well-being according to gestation age and commence chemotherapy as soon as possible. This would give the best survival chances to the mother.

Keywords: Acute myeloid leukemia, pregnancy, chemotherapy.

INTRODUCTION

The association of leukemia and pregnancy is very rare, rather under-diagnosed and sparsely reported. The prevalence based on diagnosed and reported cases is one in 75,000 to 100,000 pregnancies. Most of the leukemias diagnosed in pregnancy are myeloblastic.

Acute myeloid leukemia (AML) is characterized by excessive proliferation of blast cells of myeloid lineage. This results in hematopoietic insufficiency like anemia and thrombocytopenia. The symptoms are related to complications of the pancytopenia, such as infections or hemorrhagic diathesis. The mentioned initial symptoms of leukemia in pregnancy are easily attributed to physiological changes related to the pregnancy and hence are either missed or diagnosed late. We report a case of Acute Myeloid Leukemia in a pregnant patient, its management and outcome.

CASE PRESENTATION

18-year-old primigravida presented at 33 weeks 6 days gestation. She was referred with history of weakness since 15 days and fever, cough, cold since 3 days associated with raised leucocyte count. She belonged to low socioeconomic status, was unbooked and had two antenatal visits during her pregnancy. She visited the facility when she had symptoms of gross weakness.

Her first trimester was uneventful. She was registered at a local hospital but was not compliant. Dating scan, trisomy screening and anomaly scan was not done.

On examination, her pulse rate was 88, blood pressure 100/60, respiratory rate 20 per minute, and temperature 99 degree Fahrenheit. She was pale but there was no jaundice, icterus or edema. She had angular stomatitis, and glossitis indicating malnutrition. Lymph nodes were not palpable.

On per abdomen examination, Uterus was relaxed, 33-34 weeks size and fetal heart 143/min. Ultrasound showed a single live fetus in cephalic presentation with effective fetal weight of 2.4 kg and liquor 12.7cm. Placenta was in upper posterior position. The fetus had overdistended urinary bladder with hydronephrosis of fetal kidneys suggestive of bladder outlet obstruction. Moderate hepatosplenomegaly was present. She was moderately anemic with hemoglobin of 8.3 gm/dl. The leucocyte count was very high 2,66,000/cu mm with neutrophils 4, lymphocytes 1, eosinophils 1 and basophils 1. The blood picture showed marked leucocytosis with blasts cells predominating 86% and 2 myelocytes and 1 metamyelocyte. The blast cells typically showed large nuclei, opened up chromatin, prominent nucleoli and cytoplasmic blebs. This picture raised the suspicion of Acute Myeloid Leukemia in pregnancy. Her platelet count was 96000/cu mm. LDH was raised 995 U/L signifying cell lysis. Liver enzymes were also borderline raised. Dengue serology was found negative. Her blood group was O negative. Serum Creatinine - 1.05 mg/dl and Serum uric acid - 10.9 mg/dl were also raised. The blood picture thus indicated towards normochromic normocytic anemia, thrombocytopenia and leukocytosis. On further examination of the peripheral blood smear, a leukoerythroblastic formula was noted with the presence of predominant blast population (86%) (Figure 1).

Peripheral smear showed mostly Monoblasts (red arrow), promonocytes (green arrow) and few myeloblasts (blue arrow) under the oil immersion object 100 X, Leishman stain.

Monoblasts are large cells with abundant cytoplasm, moderately to intensely basophilic, scattered fine azurophilic granules, round nuclei with lacy chromatin and one or more large nucleoli.

Promonocytes have moderate cytoplasm, less basophilic, granulated with occasional large azurophilic granules. Vacuoles are more irregular. Nuclei are delicately folded.

Myeloblasts have large nuclei, fine chromatin, 3-4 prominent nucleoli and few Auer rods in the cytoplasm.

In view of suspected Acute Myeloid Leukemia, she was advised Bone marrow aspiration, biopsy and immunophenotyping, flow cytometry and translocation (15:17) study by oncologist.

The obstetrical examination was normal. All cardiotocographies were reactive. She was started on IV antibiotics, Inj Ceftriaxone 1 gm IV BD and steroids, Inj Betamethasone was given for fetal lung maturity. In view of malignancy with pregnancy, the case was discussed in tumor board on 10/9/19 and a decision for delivery followed by chemotherapy was taken.

She was induced with one dose of intracervical dinoprostone gel following which she went into labour and delivered live baby 2.8 kg weight with good apgar. The baby was shifted to nursery in view of premature delivery and mother was planned to transfer to medical oncology department for Induction chemotherapy.

Repeat investigations three days after delivery, haemoglobin decreased to 7 g/dl, TLC increased to 3,81,000 cells per cu mm with neutrophils 2, lymphocytes 5 and myelocytes 5. The abnormal blast cells had increased to 88% and platelets decreased to 21000 per cu mm (TABLE 1). Serum creatinine also increased to 1.43 mg/dl and e-GFR decreased to 54 ml/min/1.73 m2, indicating compromised renal function. The peripheral picture showed mostly agranuloblasts with moderate to scanty grey blue vacuolated cytoplasmic nuclei showing convolutions and 1-3 nucleoli occasional myelocytes, metamyelocytes seen, findings in favour of Acute myeloid leukemia (M4/M5). On myeloperoxidase staining, only 40 % took up the stain indicating AML-M4 lineage. She was transfused with one packed cell and one single donor platelet, following which her condition improved. She was transferred to medical oncology ward where she received chemotherapy and had immediate remission of the disease.

Table 1: Sequential Investigation Reports during hospital stay

DISCUSSION

The Incidence of Acute Myeloid Leukemia is 1 in 75,000 to 100,000 pregnancies with maximum 40% presenting in third trimester and 23% and 37% in first and second trimester respectively. In a population based study by Nolan et al [1], out of total acute leukaemia cases, two thirds are myeloblastic and one third lymphoblastic leukemia.

The rarity of disease during pregnancy, might also be due to very low reporting in view of confusing diagnosis. The symptoms of AML can easily be confused with symptoms of anaemia like malaise, easy fatigueability, low grade fever. Thrombocytopenia and anaemia are relatively common findings in pregnancy. Although, Neutropenia is rare and merits further investigation or close monitoring. But in the developing country like India, it is majorly missed. Thus, whenever there is presence of circulating blasts in a blood film, it suggests a diagnosis of haematological malignancy and is an indication for bone marrow biopsy. The other differential diagnosis that should be kept in mind are Thrombotic microangiopathy, HELLP syndrome and Cytopenias of deficiency or immune origin [2].

The tests to be done before bone marrow aspiration are Full blood count, blood film examination, Vitamin B12, folate and ferritin measurement, Coagulation screen, Renal and liver function tests. All these were done for our patient and further bone marrow aspiration was suggested with studies directed at Immunophenotypic, cytogenetic and molecular analysis for accurate subtyping and understanding of prognostic features.

Once diagnosed, a Multidisciplinary approach comprising of hematologists, obstetricians, anesthetists and neonatologists is the key to appropriate management. Consideration should be given to health of both mother and baby. The woman should be fully informed about the diagnosis, treatment of the disease and possible complications during pregnancy , clearly implying that any treatment delays might result in compromised maternal outcome without improving the outcome for the fetus [3].

The risks of Leukemia, disease per se, to pregnancy is miscarriage, foetal growth restriction, perinatal mortality, premature labour and Intrauterine fetal death [4].

Due to the high risk of the disease, there are different recommendations for management of AML in pregnancy in the three trimesters owing to the urgent need of chemotherapeutic agents and the adverse effects of the drugs involved .

If it is diagnosed in the first trimester, the patient should be counselled for elective abortion, medical/surgical and starting of chemotherapy. Between 13- 24 weeks, the Induction chemotherapy should be started while pregnancy is continued [5]. Preterm termination of pregnancy is indicated after fetal viability. Similar conclusions were derived by Nicola et al and Farhadfar in a single centre study of 5 and 23 case of AML diagnosed during pregnancy respectively [6,7].

Between 24 - 32 weeks, chemotherapy exposure to the fetus must be balanced against risks of prematurity following elective delivery at that stage of gestation (Grade 1C). At gestation age more than 32 weeks, the fetus should be delivered prior to Induction chemotherapy.

Chemotherapy with anthracycline based regimens are favored. According to a meta-analysis done by Natanel A Horowitz et al, anthracycline based regimens were associated with maximum remission but overall maternal survival was very low (30%)[8]. Even in our case, although the mother immediately had remission with chemotherapy. There was a recurrence after disease free 10 months and she succumbed to the disease during the COVID pandemic. Quinolones, tetracyclines and sulphonamides are better avoided in pregnancy(Grade 1B).

In one case report by Abdullah et al, a trial of 5- azacytidine has shown promising results [9]. The antifungal of choice in pregnancy is Amphotericin B or lipid derivatives (Grade 2C). If blood transfusion is needed, the blood should be screened for Cytomegalovirus (Grade 1B). Supportive therapy like a course of Corticosteroids given if delivery is between 24 and 35 weeks gestation (Grade 1A) [10]. Magnesium sulphate should be considered 24 h prior to delivery before 30 weeks gestation (Grade 1A).

Delivery should be planned for a time when the woman is at least 3 weeks post-chemotherapy to minimize risk of neonatal myelosuppresion (Grade 1C). Planned delivery is preferred, like Induction of labour (Grade 2C). Caesarean section is indicated only for obstetric indications. Epidural analgesia is better avoided.

The Dose of chemotherapy is calculated on their actual body weight with dose adjustments for weight gain during pregnancy owing to various pregnancy changes.

The Chemotherapy agents have a MW of 250-400 KDa and hence can cross the placenta resulting in detrimental teratogenic effects on developing fetus.Sunny J. Patel et al have done a comprehensive analysis on outcomes in hospitalized pregnant patients with acute myeloid leukemia and come to conclusion that a multidesciplinary, holistic approach leads to quick remission of the disease [11]

After delivery, histopathologic examination of placenta to rule out placental transfer to fetus is advisable. Cytologic examination should be performed in both maternal and umbilical cord blood and neonates should be clinically examined for palpable skin lesions, organomegaly or other masses. If the baby is found to be healthy, a follow up after every six months for two years is recommended. In each visit, physical examination, chest x-ray and liver function tests should be done.

CONCLUSION

Acute myeloid leukemia in pregnancy is a Rare diagnosis and even rarely reported. With the trend for delaying pregnancy into the later reproductive years, we expect to see more cases of cancer complicating pregnancy. Presently, there are no clear management guidelines to address timing and dosing of anthracycline/cytarabine based regimens especially in pregnancy. The potential drug toxicity to mother and fetus and transplant considerations in intermediate and highrisk patients during pregnancy has not been addressed.

What we also need today is a National registry for leukemia patients, treated in pregnancy. This will help us to answer many unanswered queries and improve maternal and fetal overall survival rates. Although we have few comprehensive studies, but further studies and references are needed. Finally, a Multidisciplinary team is needed to provide comprehensive care to patients.

For more information: https://jmedcasereportsimages.org/about-us/

For more submission : https://jmedcasereportsimages.org/

#Acute myeloid leukemia #pregnancy #chemotherapy #AML #cytoplasm #leukoerythroblastic #hematologists #obstetricians #anesthetists #Vina Kumari #jcrmhs

0 notes

thelaughingspaceman · 2 years

Note

Hello. I'm Esther and I'm sending this to you on behalf of my girlfriend(NiNi), who have been diagnosed with Acute Myeloid Leukemia (AML). With the help of friends and some LGBTQ community, we have been able to commence treatment for my beloved girlfriend, but things escalated quickly based on the nature of the ailment. We currently are not financially capable to treat it as fast as we should. It's getting worse and that's why I'm pleading for your support towards Nini's treatment. We'd appreciate your donation if you can, i've chosen a platform which accepts as low as $1, this shows how urgent and desperate we her to continue her treatments.

Please click here to read more and donate if you can - spot.fund/SaveMyLeukemiaGirlfriend

You can read the post I made about on my blog.(I have the link on my description/bio).Your support is so more appreciated. Thank you .

Unfortunately I'm not in a position to donate :( but I can spread the word to whomever follows me and they might be able to!

#donation post #financial aid #help needed #please donate #acute myeloid leukemia #spot fund #pls help if you can!

0 notes

reportwire · 2 years

Text

Large International Study Pinpoints Impact of TP53 Mutations on Blood Cancer Severity

“Our findings are of immediate clinical relevance to MDS patients,” Dr. Papaemmanuil says. “Going forward, all MDS patients should have their TP53 status assessed at diagnosis.” As for why it takes two “hits” to TP53 to see an effect on cancer outcomes, Dr. Elsa Bernard, a postdoctoral scientist in the Papaemmanuil lab and the study’s first author, speculates that having one normal copy is enough…

View On WordPress

#acute myeloid leukemia #blood cancer #hematology #MDS #oncology #TP53 gene

0 notes

kajmasterclass · 3 days

Text

youtube

#The Power of Homeopathy and Shamanic Coaching with Sarah Thompson | KAJ Masterclass Join Sarah Thompson #a certified homeopath and shamanic coach #as she shares her powerful approach to deep healing on physical #mental #and emotional levels. Having overcome acute myeloid leukemia #Sarah brings a unique perspective on leveraging symptoms for personal growth and breakthroughs. In this insightful episode #she demystifies the worlds of homeopathy and shamanic coaching #offering a holistic path to profound health and well-being. Whether you're struggling with chronic conditions #anxiety #depression #or feeling stalled on your healing journey #Sarah's expertise promises to provide invaluable wisdom and strategies for unlocking your full healing potential.#Youtube

0 notes

kenresearch1 · 5 months

Text

The Transformative Growth of the US Acute Myeloid Leukemia Market

Buy Now

What is the Size of US Acute Myeloid Leukemia Industry?

US Acute Myeloid Leukemia Market is expected to grow at a CAGR of ~ % in 2022 and is expected to reach ~USD Mn by 2028. The US Acute Myeloid Leukemia market is the rapid advancement in precision medicine and targeted therapies. The emergence of innovative treatments tailored to the genetic and molecular characteristics of individual AML patients has transformed the treatment landscape. Targeted therapies, such as FLT3 and IDH inhibitors, capitalize on specific genetic mutations driving AML, resulting in higher response rates and improved outcomes compared to traditional approaches.

Precision medicine's ability to identify the most effective treatment for each patient not only enhances therapeutic efficacy but also reduces unnecessary treatments, mitigating side effects and improving overall quality of life. This paradigm shift is bolstered by technological progress in molecular profiling techniques like next-generation sequencing, allowing for accurate genetic profiling and treatment customization.

Furthermore, regulatory support and accelerated approval pathways for targeted therapies have expedited their availability to patients. Pharmaceutical companies' increasing investment in research and development of novel agents, along with collaborations between academia and industry, leads to grow this market even more.

Click here to Download a Sample Report

US Acute Myeloid Leukemia Market by treatment type

The market is segmented by Treatment type into Chemotherapy, Targeted Therapy, Hormone Therapy, Immunotherapy and Others. Targeted Therapy is the dominant segment in the US Acute Myeloid Leukemia market in 2022. Specialty Centers, dedicated to the diagnosis, treatment, and management of specific medical conditions like AML, offer a concentrated and specialized approach to patient care. Their dominance in the AML market is driven by their unique capabilities to provide comprehensive and tailored treatments that address the complex needs of AML patients.

US Acute Myeloid Leukemia Market by end -user industry

The market is segmented by End-User into Hospitals, Homecare, Specialty Centers, Pharmacies and Others. Among these, Specialty Centers are the dominant End-User in the US Acute Myeloid Leukemia market in 2022. Specialty centers have a higher level of expertise and experience in treating specific types of cancer, including acute leukemia. They typically have specialized medical professionals, including hematologists and oncologists, who are well-versed in the latest treatment protocols and research. These centers are equipped with state-of-the-art diagnostic and treatment facilities that are specifically tailored to the needs of leukemia patients. This can include advanced imaging technologies, specialized laboratories, and access to cutting-edge therapies.

Click here to Download a Custom Report

US Acute Myeloid Leukemia companies market by Region

The US Acute Myeloid Leukemia market is segmented by Region into North, South, East, West. The dominance region is North in the US Acute Myeloid Leukemia Market in 2022. the North region often benefits from a higher level of funding for medical research, including AML. Federal funding agencies, private foundations, and pharmaceutical companies frequently channel resources into institutions within this region, allowing for greater research capabilities and clinical trials infrastructure.

Competition Scenario in US Acute Myeloid Leukemia Market

The US acute myeloid leukemia market was characterized by the presence of several prominent pharmaceutical companies and biotechnology firms striving to establish their presence and gain a competitive edge.

Larger corporations, smaller biotechnology companies making significant contributions to the AML landscape. Companies like Agios Pharmaceuticals and Daiichi Sankyo were gaining attention for their novel therapies targeting AML-associated mutations. These players are often at the forefront of introducing precision medicine approaches to AML treatment, taking advantage of advancements in genetic profiling and molecular diagnostics.

The competition is further intensified by research collaborations and partnerships between pharmaceutical companies, academic institutions, and research organizations. These collaborations aimed to combine resources, expertise, and insights to accelerate the development of effective therapies.

What is the Expected Future Outlook for the Overall US Acute Myeloid Leukemia market?

The US Acute Myeloid Leukemia market was valued at USD ~Million in 2022 and is anticipated to reach USD ~ Million by the end of 2028, witnessing a CAGR of ~% during the forecast period 2022- 2028. Pharmaceutical companies have been actively researching and developing novel therapies for Acute Myeloid Leukemia, with a focus on improving patient outcomes and reducing the side effects associated with traditional treatments like chemotherapy. The approval of new drugs, such as FLT3 and IDH inhibitors, has offered fresh therapeutic avenues for specific subsets of Acute Myeloid Leukemia patients with genetic mutations.

The future outlook for the US Acute Myeloid Leukemia market is anticipated to be influenced by a combination of factors including advancements in treatment options, evolving regulatory landscapes, and a growing understanding of the molecular basis of Acute Myeloid Leukemia. The market has been witnessing a shift towards personalized medicine, with increasing emphasis on targeted therapies and precision medicine approaches.

Furthermore, the integration of innovative technologies like next-generation sequencing (NGS) has enhanced our understanding of Acute Myeloid Leukemia’s molecular complexities, allowing for better patient stratification and treatment selection. This trend toward molecular profiling and personalized treatment regimens is likely to continue shaping the market landscape.

However, challenges persist. Despite progress, Acute Myeloid Leukemia remains a difficult-to-treat disease with a high relapse rate. Overcoming drug resistance and developing effective strategies for patients who do not respond well to existing therapies remain critical areas of focus.

Additionally, the cost of novel therapies and access to these treatments could also impact their adoption and availability. The regulatory environment, including expedited pathways for drug approvals, continue to influence market dynamics.

0 notes